- $12.33bn
- $24.27bn
- $13.64bn
DaVita lifts lower end of 2026 profit forecast, shares fall
DaVita buys back $69 million shares from Berkshire, which retains 45% stake
Corrected: DaVita Q3 revenue beat analyst estimates on increased average reimbursement rates
Brief: DaVita Q3 Revenue USD 3,578 Million Vs. IBES Estimate USD 3,508 Million
FMC slips after new US kidney-care strategy
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Brief: Davita Announces New Value-Based Partnership With Humana To Expand Care For Patients With Chronic Kidney Disease
Alphabet becomes Berkshire Hathaway's third-largest investment (updated)
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
U.S. STOCKS ON THE MOVE-Walt Disney, Alphabet, Kraft Heinz
U.S. STOCKS ON THE MOVE-Wynn Resorts, Griffon, Kratos Defense, Amgen
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
U.S. STOCKS ON THE MOVE-Cencora, Charles River, Twist Bioscience
U.S. STOCKS ON THE MOVE-Arista Networks, CVS, Eli Lilly, Phillips 66
DaVita falls after flagging lower revenue per treatment
DaVita flags lower revenue per treatment, reaffirms annual forecast
DaVita Inc reports results for the quarter ended June 30 - Earnings Summary
Berkshire sells 182,980 DaVita shares, still has 45% stake in dialysis provider